Chronic liver damage leads to scarring (fibrosis) of the liver tissue, which can ultimately lead to increased blood pressure in the vascular system of the gastrointestinal tract (i.e. portal hypertension).
Portal hypertension can result in serious complications.
A recent from MedUni Vienna found that the increasing severity of portal hypertension is paralleled by inflammatory reactions in the body (systemic inflammation).
They found that common high blood pressure drug beta-blockers have anti-inflammatory effects in advanced liver disease.
Beta-blockers have been used as standard drug treatment, but only 50% to 60% of patients achieve a clinically relevant reduction in portal vein pressure.
The study shows for the first time that beta-blockers also have an impact on systemic inflammation.
The study was published in Gut and conducted Thomas Reiberger.
In this study, the researchers found biomarkers of systemic inflammation prior to and subsequently during treatment with beta-blockers.
They showed that patients suffering from advanced stages of cirrhosis were not only more likely to have a systemic inflammatory response but were also more likely to benefit from the anti-inflammatory effects of beta-blockers.
The cirrhotic patients achieved a reduction in inflammatory markers (such as the white blood cell count) under beta-blocker therapy, and they had much fewer complications of portal hypertension and lower death risk.
The team says after further validation in clinical trials, these findings may help to predict the benefit of beta-blocker treatment more accurately and thus give patients optimal advice.
If you care about blood pressure, please read studies about how to monitor blood pressure at home correctly, and plant-based foods could benefit people with high blood pressure.
For more information about blood pressure, please see recent studies about added sugar in your diet linked to higher blood pressure, and results showing plant pigment can strongly reduce blood pressure.
Copyright © 2022 Knowridge Science Report. All rights reserved.